Ladies and gentlemen, thank you for joining us today. Welcome to the Compugen Ltd. Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] An audio webcast of this call is ...
HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...
Gilead’s upfront and IND milestone payments, together with future milestone eligibility for GS-0321, provide diversified, multi-year external funding sources. Partner statements repeatedly cited ...
Compugen Ltd. beats earnings expectations. Reported EPS is $0.6, expectations were $0.05. Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen Ltd.’s Fourth Quarter and ...
Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.06. Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s First Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results